ERIS LIFESCIENCES LIMITEDEE

ERIS LIFESCIENCES LIMITED

1,214.50INRD
−21.95−1.78%
At close at Feb 27, 11:08 GMT
INR
No trades
See on Supercharts

ERIS fundamentals

Key facts

Market capitalization‪168.32 B‬INR
Founded2007
Employees (FY)‪3.08 K‬
CEOAmit Indubhushan Bakshi
Websiteeris.co.in
About

Eris Lifesciences Ltd. engages in the provision of pharmaceutical products. Its brands include Eritel, Glimsave, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The firm markets and distributes pharmaceutical drugs, such as tablets, syrups and injections. The company was founded by Amit Indubhushan Bakshi on January 25, 2007 and is headquartered in Ahmedabad, India.

Ownership
‪‪136.13 M‬‬
Closely held shares
‪‪94.64 M‬‬ (69.52%)
Free Float shares
‪‪41.49 M‬‬ (30.48%)
Closely held shares
‪‪94.64 M‬‬ (69.52%)
Free Float shares
‪‪41.49 M‬‬ (30.48%)
Capital structure
Market cap
‪‪168.32 B‬‬
Enterprise value
‪‪168.32 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪168.32 B‬‬
Price to earning ratio (P/E)
51.16x
Price to sales ratio (P/S)
6.15x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
51.16x
Price to sales ratio (P/S)
6.15x
Valuation ratios
‪0.00‬
‪2.00‬
‪4.00‬
‪6.00‬
‪8.00‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪15.00‬
‪30.00‬
‪45.00‬
‪60.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪10%‬
‪13%‬
‪16%‬
‪19%‬
‪22%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪‪2.00 B‬‬
‪‪4.00 B‬‬
‪‪6.00 B‬‬
‪‪8.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪2.00 B‬‬
‪‪4.00 B‬‬
‪‪6.00 B‬‬
‪‪8.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪2.00 B‬‬
‪‪4.00 B‬‬
‪‪6.00 B‬‬
‪‪8.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Pharmaceuticals
By country
Period: 2023
India

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪2.00 B‬‬
‪‪4.00 B‬‬
‪‪6.00 B‬‬
‪‪8.00 B‬‬
Actual
Estimate
Earnings
Next:May 27, 2025
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪2.00‬
‪4.00‬
‪6.00‬
‪8.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
30.37%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
0.00%
Last payment
7.35
Last ex-date
Feb 13, 2025
Dividend history
‪0.00%‬
‪0.35%‬
‪0.70%‬
‪1.05%‬
‪1.40%‬
2019
2020
2021
2022
2023
‪0.00‬
‪2.00‬
‪4.00‬
‪6.00‬
‪8.00‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪‪7.00 B‬‬
‪‪14.00 B‬‬
‪‪21.00 B‬‬
‪‪28.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
Assets
Liabilities